Treating Atopic dermatitis with IgE antagonists
AssigneeTanox, Inc.
InventorTse-Wen Chang
Life of this patent
Estimating the term…
Abstract
The invention relates to a composition for treatment of atopic dermatitis comprising a suitable IgE antagonist that does not induce the release of mediators of allergy; for example, anti-IgE antibodies that bind to secreted IgE, membrane IgE on the surface of IgE-producing B cells, but not to IgE bound to the FcεRI on the surface of basophils or mast cells. Preferably, these antibodies also do not bind to IgE bound to FcεRII receptors. It is also preferable if these antibodies have human IgG1 or IgG3 constant regions, as well as further human portions, if desired. The composition can be administered systemically or topically.
Claims13
A method for treating atopic dermatitis comprising administering to a host in need of such treatment a composition comprising an IgE antagonist.
A method for treating atopic dermatitis comprising administering to a host in need of such treatment a composition comprising an anti-IgE antibody which binds to secreted IgE but not to basophils.
A method for treating atopic dermatitis comprising administering to a host in need of such treatment a composition comprising an anti-IgE antibody, which binds to secreted IgE and membrane-bound IgE, but not to basophils.
A method for treating atopic dermatitis comprising administering to a host in need of such treatment a composition comprising an anti-IgE antibody which binds to secreted IgE and membrane-bound IgE but not to basophils and not to IgE which is bound to the FcεRII receptor.
Dependencies are inferred from the claim text.